Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have been assigned an average recommendation of “Hold” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $13.75.

Several equities analysts recently commented on JNCE shares. HC Wainwright set a $13.00 price objective on shares of Jounce Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. Zacks Investment Research raised shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Tuesday, August 14th. JPMorgan Chase & Co. reduced their price objective on shares of Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating for the company in a research note on Friday, August 10th. Cowen reaffirmed a “hold” rating on shares of Jounce Therapeutics in a research note on Tuesday, November 13th. Finally, Raymond James reduced their price objective on shares of Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, October 23rd.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its position in Jounce Therapeutics by 4.0% during the third quarter. BlackRock Inc. now owns 1,450,680 shares of the company’s stock valued at $9,429,000 after purchasing an additional 55,775 shares during the last quarter. Redmile Group LLC lifted its position in Jounce Therapeutics by 2.7% during the second quarter. Redmile Group LLC now owns 1,214,593 shares of the company’s stock valued at $9,304,000 after purchasing an additional 32,200 shares during the last quarter. Vanguard Group Inc. lifted its position in Jounce Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 776,016 shares of the company’s stock valued at $5,045,000 after purchasing an additional 41,945 shares during the last quarter. Millennium Management LLC lifted its position in Jounce Therapeutics by 91.6% during the second quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after purchasing an additional 324,681 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock valued at $2,861,000 after purchasing an additional 266,126 shares during the last quarter. Institutional investors and hedge funds own 82.60% of the company’s stock.

NASDAQ:JNCE traded down $0.24 during mid-day trading on Monday, hitting $3.95. 299,046 shares of the stock traded hands, compared to its average volume of 271,886. The stock has a market cap of $137.01 million, a P/E ratio of -6.93 and a beta of 5.00. Jounce Therapeutics has a 12-month low of $3.30 and a 12-month high of $29.25.

Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.11. The company had revenue of $14.53 million during the quarter, compared to analysts’ expectations of $12.80 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. On average, equities analysts anticipate that Jounce Therapeutics will post -1.14 earnings per share for the current year.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Read More: What are earnings reports?

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.